stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) Free cash flow
Dr. Reddy's Laboratories Ltd's free cash flow for fiscal 2026 was $215.0M, up 36.9% from $157.0M in fiscal 2025. Over the twelve months to 30 September 2026 it was $96.0M. Over the past ten years it has ranged from −$299.0M (fiscal 2017) to $487.0M (fiscal 2023); the current reading is higher than 50% of that period. Dr. Reddy's Laboratories Ltd ranks 23rd of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | $215.0M | 36.94% |
| FY2025 | $157.0M | (31.74%) |
| FY2024 | $230.0M | (52.77%) |
| FY2023 | $487.0M | 198.77% |
| FY2022 | $163.0M | (48.58%) |
| FY2021 | $317.0M | (0.94%) |
| FY2020 | $320.0M | (1.23%) |
| FY2019 | $324.0M | 197.25% |
| FY2018 | $109.0M | — |
| FY2017 | −$299.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $18.0M | — |
| Jun 2026 | −$23.0M | — |
| Mar 2026 | $58.0M | 34.88% |
| Dec 2025 | $43.0M | (29.51%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| VTRS Viatris Inc. compare | $2.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.0B |
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| ALKS Alkermes plc compare | $228.4M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $197.2M |
| RDY Dr. Reddy's Laboratories Ltd | $96.0M |
| HIMS Hims & Hers Health, Inc. compare | $83.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −$60.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement